These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 22976073

  • 1. Methods for measuring tau pathology in transgenic mouse models.
    Forest SK, Acker CM, d'Abramo C, Davies P.
    J Alzheimers Dis; 2013; 33(2):463-71. PubMed ID: 22976073
    [Abstract] [Full Text] [Related]

  • 2. Isolation and Detection of Pathological Tau Species in a Tauopathy Mouse Model.
    Singh AK, Selvarasu K, Durairajan SSK.
    Methods Mol Biol; 2024; 2761():317-328. PubMed ID: 38427247
    [Abstract] [Full Text] [Related]

  • 3. Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
    Sahara N, Vega IE, Ishizawa T, Lewis J, McGowan E, Hutton M, Dickson D, Yen SH.
    J Neurochem; 2004 Aug; 90(4):829-38. PubMed ID: 15287888
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.
    Sahara N, DeTure M, Ren Y, Ebrahim AS, Kang D, Knight J, Volbracht C, Pedersen JT, Dickson DW, Yen SH, Lewis J.
    J Alzheimers Dis; 2013 Aug; 33(1):249-63. PubMed ID: 22941973
    [Abstract] [Full Text] [Related]

  • 11. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
    Boluda S, Iba M, Zhang B, Raible KM, Lee VM, Trojanowski JQ.
    Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
    [Abstract] [Full Text] [Related]

  • 12. The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties.
    Matsumoto SE, Motoi Y, Ishiguro K, Tabira T, Kametani F, Hasegawa M, Hattori N.
    Hum Mol Genet; 2015 Nov 15; 24(22):6403-16. PubMed ID: 26374846
    [Abstract] [Full Text] [Related]

  • 13. Methods for Biochemical Isolation of Insoluble Tau in Rodent Models of Tauopathies.
    Canet G, Rocaboy E, Diego-Diàz S, Whittington RA, Julien C, Planel E.
    Methods Mol Biol; 2024 Nov 15; 2754():323-341. PubMed ID: 38512674
    [Abstract] [Full Text] [Related]

  • 14. Pharmacogenetic neuronal stimulation increases human tau pathology and trans-synaptic spread of tau to distal brain regions in mice.
    Schultz MK, Gentzel R, Usenovic M, Gretzula C, Ware C, Parmentier-Batteur S, Schachter JB, Zariwala HA.
    Neurobiol Dis; 2018 Oct 15; 118():161-176. PubMed ID: 30049665
    [Abstract] [Full Text] [Related]

  • 15. Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy.
    Delobel P, Lavenir I, Fraser G, Ingram E, Holzer M, Ghetti B, Spillantini MG, Crowther RA, Goedert M.
    Am J Pathol; 2008 Jan 15; 172(1):123-31. PubMed ID: 18079436
    [Abstract] [Full Text] [Related]

  • 16. Elevated levels of soluble total and hyperphosphorylated tau result in early behavioral deficits and distinct changes in brain pathology in a new tau transgenic mouse model.
    Flunkert S, Hierzer M, Löffler T, Rabl R, Neddens J, Duller S, Schofield EL, Ward MA, Posch M, Jungwirth H, Windisch M, Hutter-Paier B.
    Neurodegener Dis; 2013 Jan 15; 11(4):194-205. PubMed ID: 22797329
    [Abstract] [Full Text] [Related]

  • 17. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
    Pérez M, Ribe E, Rubio A, Lim F, Morán MA, Ramos PG, Ferrer I, Isla MT, Avila J.
    Neuroscience; 2005 Jan 15; 130(2):339-47. PubMed ID: 15664690
    [Abstract] [Full Text] [Related]

  • 18. Protocols for Monitoring the Development of Tau Pathology in Alzheimer's Disease.
    Rábano A, Cuadros R, Merino-Serráis P, Rodal I, Benavides-Piccione R, Gómez E, Medina M, DeFelipe J, Avila J.
    Methods Mol Biol; 2016 Jan 15; 1303():143-60. PubMed ID: 26235064
    [Abstract] [Full Text] [Related]

  • 19. Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions.
    Petry FR, Pelletier J, Bretteville A, Morin F, Calon F, Hébert SS, Whittington RA, Planel E.
    PLoS One; 2014 Jan 15; 9(5):e94251. PubMed ID: 24788298
    [Abstract] [Full Text] [Related]

  • 20. Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies.
    Julien C, Bretteville A, Planel E.
    Methods Mol Biol; 2012 Jan 15; 849():473-91. PubMed ID: 22528110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.